A Study Exploring Sotatercept and Ruxolitinib in MPN-Associated Myelofibrosis and Anemia

January 17, 2018
Prithviraj Bose, MD

Prithviraj Bose, MD, an associate professor in the Department of Leukemia, Division of Cancer Medicine, at The University of Texas MD Anderson Cancer Center, discusses a study exploring sotatercept (ACE-011) alone and in combination with ruxolitinib (Jakafi) in patients with myeloproliferative neoplasm (MPN)-associated myelofibrosis and anemia. 

Prithviraj Bose, MD, an associate professor in the Department of Leukemia, Division of Cancer Medicine, at The University of Texas MD Anderson Cancer Center, discusses a study exploring sotatercept (ACE-011) alone and in combination with ruxolitinib (Jakafi) in patients with myeloproliferative neoplasm (MPN)-associated myelofibrosis and anemia.

This single-arm, open-label, phase II trial included 2 cohorts of patients, with one receiving sotatercept alone, and the other receiving sotatercept added to ruxolitinib.